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ABSTRACT 
Objective: A simple and stability-indicating high-performance thin-layer chromatographic method was developed and validated for the 
simultaneous estimation of metformin and alogliptin in tablets.  
Methods: The method was developed in TLC aluminum plates pre-coated with silica gel 60F254 
Results: The developed method was found to be suitable for the excellent separation of the drug samples. Calibration curves were linear in the 
range of 40-200 ng/spot with a correlation coefficient of 0.996 for metformin and calibration curves were linear in the range of 1-5 ng/spot with a 
correlation co-efficient of 0.997 for alogliptin, respectively. Stability study shows that the chromatograms of samples degraded with acid, base, 
hydrogen peroxide, dry heat, and photolytic showed well-separated spots of pure metformin and alogliptin as well as some additional peaks at 
different Rf values. The method was successively applied to pharmaceutical formulation. No chromatographic interference from the tablet 
excipients was found. 
as the stationary phase and the solvent system 
consists of methanol: chloroform: 0.5% ammonium sulphate [4:4:2, v/v/v]. The system was found to conferred a compact spot for metformin [Rf 
value of 0.44±0.02] and alogliptin [Rf value of 0.66 ± 0.22]. Densitometric analysis of metformin and alogliptin was carried out at the wavelength of 
254 nm. Forced degradation studies were conducted to know the stability of the drug samples under various stress conditions like acid, base, 
peroxide, photolytic degradation according to the ICH guidelines.  
Conclusion: The newly developed method can be applied for the identification and quantitative determination of metformin and alogliptin in the 
combined dosage form. 
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INTRODUCTION 
Metformin hydrochloride is chemically N; N-Dimethylimido 
dicarbon imidic diamide. The chemical classification of metformin is 
a biguanide. The biguanide classes of anti-diabetic with an anti-
hyperglycemic drugs are used in the treatment of type-2 diabetic 
patients. The classes of medications, particularly those which work 
via the incretin pathway, achieve glucose-lowering and minimizing 
risks ideally. The combination should be well-tolerated, convenient 
to take, should have few contraindications, a low risk of 
hypoglycemia, weight gain and be reasonably effective over both the 
short and long term such as the combination of metformin and 
alogliptin is a dipeptidyl peptidase-4 [DPP-4] inhibitor which is used 
in combination in the therapy of type 2 diabetes [1]. 
 
 
Fig. 1: Chemical structure of metformin 
 
 
Fig. 2: Chemical structure of Alogliptin 
Alogliptin is an orally administered antidiabetic drug in the 
dipeptidyl peptidase-4[DPP-4]. DPP-4 inhibitors represents a new 
therapeutic approach to the treatment of type 2 diabetes that 
functions to stimulate glucose-dependent insulin release and reduce 
glucagon’s levels. This is done through inhibition of the inactivation 
of incretins, particularly glucagon-like peptide-1 [GLP-1] and gastric 
inhibitory polypeptide [GIP]. Alogliptin inhibits dipeptidyl peptidase 
4[DPP-4], which normally degrades the incretin glucose-dependent 
insulin tropic polypeptide [GIP] and glucagon-like peptide1 [GLP-1], 
thereby improving glycemic control [2]. A combination of both drugs 
is recently launched in the market. The chemical structures of the 
drugs are shown in fig. 1, fig. 2, respectively. Literature survey reveals 
that spectrophotometric [3-5], High-Performance Liquid 
chromatography [HPLC] [6-8] and high-performance thin-layer 
chromatography [HPTLC] [9-11] methods for the estimation of 
metformin alone or in combination with other drugs from 
pharmaceutical formulation have been developed whereas 
spectrophotometric [12-14], RP-HPLC [15-17], HPTLC [18] and LC-
MS/MS [19] methods for the estimation of alogliptin alone or in 
combination with other drugs from pharmaceutical formulation have 
been developed. However, no stability-indicating method has been 
reported so far simultaneous estimation of both drugs in combined 
pharmaceutical dosage form by HPTLC. The current method is the first 
method used so far for the simultaneous estimation of the alogliptin 
and metformin by HPTLC method. The advantages of HPTLC are, a 
large number of samples can be simultaneously analyzed in a shorter 
period. Unlike HPLC, this method utilizes fewer quantities of solvents, 
thus lowering the cost of analysis. 
The ideal stability-indicating chromatographic method should 
estimate the drug and also be able to resolve the drug from its 
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degradation products. Hence an attempt has been made to develop 
an accurate, rapid and reproducible method for the determination of 
metformin and alogliptin in presence of their degradation products 
for their content analysis in pharmaceutical dosage forms, 
containing this combination as per ICH guidelines [20]. 
MATERIALS AND METHODS 
Metformin Hcl was received from Cadila pharmaceutical, 
Ahmedabad; Gujarat. Alogliptin was kindly supplied by Vivan Life 
sciences, Thane, Maharashtra. All other chemicals like methanol, 
ammonium sulphate and chloroform were used for AR grade.  
HPTLC method 
Instrumentation 
Camag HPTLC system equipped with Linomat V sample applicator 
operated under a gentle stream of nitrogen, coupled with 100 µl 
HAMILTON syringe and CAMAG TLC scanner 3 controlled by 
WINCATS software was used for the application and detection of 
spots respectively. The Chromatographic separations of drugs were 
performed using pre-coated silica gel TLC aluminum plate 60 F254
Selection of mobile phase and optimization of condition 
 
[10 cm x10 cm] with 250 µm thickness and a CAMAG twin trough 
chamber was used for the chromatographic development. 
Initially, chloroform: methanol in ratio 4:6 [v/v] was tried for both drugs 
simultaneously. The spots were not developed properly and dragging 
was observed. Then chloroform: methanol in the ratio 6: 4 [v/v] was 
tried. The developed spots were diffused to the above mobile phase; 2 ml 
of 0.5 % ammonium sulphate was added. Both the peaks were 
symmetrical and no tailing was observed. Finally, the mobile phase 
consisting of chloroform: methanol: 0.5 % ammonium sulphate [4:4:2, 
v/v] gave good resolution. By optimizing chromatographic conditions 
such as having chamber saturation for 20 min, using 10 ml of the mobile 
phase and activating the plates before spotting, we obtain a good 
resolution as well as a sharp and symmetrical peak with Rf value of 0.44 
±0.02 for metformin and 0.66 ±0.02 for alogliptin. 
Chromatographic condition 
For chamber saturation, 20 ml of the mobile phase was transferred 
into the development tank with the lid closed. The assembly was 
aside for 20 min under room temperature. The Plates were 
prewashed with methanol and activated at 110 °C for 5 min before 
chromatography. The mobile phase consists of methanol: 
chloroform: 0.5% ammonium sulphate [4:4:2, v/v/v]. The plate was 
air-dried using an air dryer after the application of spots and the 
development but before densitometric scanning. The source of 
radiation utilized was a deuterium lamp. The evaluation was 
performed using peak areas with concentration. 
Preparation of standard solutions 
A combined standard stock solution containing 4000 µg/ml of 
metformin and 100 µg/ml of alogliptin was prepared in methanol. 
The application of standards was done by Hamilton syringe with the 
help of automatic sample applicator Linomat V on the TLC plate that 
gave a concentration, 40-200 ng/spot of metformin and 1-5 ng/spot 
of alogliptin, respectively. Each concentration was spotted five times 
on the TLC plates. The plates were developed using the previously 
described mobile phase. The calibration graph was plotted as peak 
areas versus corresponding concentrations. 
Analysis of marketed formulation 
To determine the content of metformin and alogliptin simultaneously 
in conventional tablets, [label claim containing 500 mg metformin and 
12.5 mg alogliptin] twenty tablets were accurately weighed. The 
average weight was calculated and ground to a fine powder. A quantity 
of powder equivalent to 400 mg metformin and 10 mg alogliptin was 
transferred into a 100 ml volumetric flask containing 50 ml methanol 
was sonicated for 30 min and diluted to mark with the same solvent. 
The resulting solution was filtered using 0.45 µm Millifilter. The 
aliquots solutions are applied on the TLC plate. The analysis was 
repeated for six times. Metformin and alogliptin gave sharp and well-
defined peaks at Rf 0.44 ± 0.02 and 0.66 ± 0.02 respectively when 
scanned at 254 nm [fig. 3]. 
 
 
Fig. 3: Densitogram of standard metformin and alogliptin 
 
Validation of HPTLC method 
Accuracy 
Accuracy of the method was determined by replicates [n=3] analysis 
and was carried out using three solutions prepared by standard 
addition of pure active pharmaceutical ingredient at three different 
concentration levels 80%,100%, and 120%. Accuracy was calculated 
by comparing the difference between the spiked value [theoretical 
value] and the found value [9, 10]. 
Precision  
Intra-day precision 
Intra-day precision was found out by carrying out the analysis of the 
standard drug at three different concentrations of 80,120 and 160 
ng/spot for metformin; 2, 3 and 4 ng/spot for alogliptin were 
selected from linearity range. The intraday analysis was carried on 
the same day in three replicates. Each concentration was applied in 
duplicate and % RSD was calculated [11, 12]. 
Inter-day precision 
Inter-day precision was found out by carrying out the analysis of the 
standard drug at three different concentrations of 80,120 and 160 
ng/spot for metformin; 2, 3, and 4 ng/spot for alogliptin were 
selected from linearity range. The interday analysis was carried on 
three different days in three replicates. Each concentration was 
applied in duplicate and % RSD was calculated [11, 12]. 
Repeatability 
Repeatability was determined by applying the corresponding µl of a 
standard solution containing 120 ng/spot of metformin and 3 
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ng/spot of alogliptin in six replicates and the respective areas were 
calculated. The % RSD was calculated [11, 12]. 
Forced degradation studies 
Forced degradation of each drug substance was carried out under acid, 
base, hydrolytic, oxidation, photolytic and thermal stress conditions. A 
thermal and photodegradation study was carried out in a solid-state. 
Solutions were prepared by dissolving drug substances in a small 
volume of methanol and later diluted with hydrochloric acid, 0.1N 
sodium hydroxide or hydrogen peroxide to achieve a concentration of 
100 µg/ml of each metformin and alogliptin [16]. 
Preparation of acid-induced degradation product 
The 40 mg of metformin and 1 mg alogliptin in 10 ml volumetric 
flask to add 1 ml of 0.1M hydrochloric acid and make up the volume 
with mobile phase then refluxed at 40 °C for 30 min. After 
completion of 30 min, about 1 ml of the above solution was taken 
and diluted up to 10 ml with methanol. The resultant solution was 
applied to TLC plates in triplicates. The chromatograms run as 
described in section [16]. 
Preparation of base induced degradation product 
The 40 mg of metformin and 1 mg of alogliptin in 10 ml volumetric 
flask to add 1 ml of 0.1M sodium hydroxide and make up the volume 
with mobile phase then refluxed at 40 °C for 30 min. After 
completion of 30 min, about 1 ml of the above solution was taken 
and diluted up to 10 ml with methanol. The resultant solution was 
applied to TLC plates in triplicates [17]. 
Preparation of hydrogen peroxide-induced degradation 
product 
The 40 mg of metformin and 1 mg of alogliptin in 10 ml volumetric 
flask to add 1 ml of 0.1M 30% hydrogen peroxide and make up the 
volume with mobile phase then refluxed at 40 °C for 30 min. After 
completion of 30 min, about 1 ml of the above solution was taken, 
neutralized and diluted up to 10 ml with methanol. The resultant 
solutions were applied to TLC plates in triplicates [17]. 
Preparation of light heat degradation products 
The 40 mg of metformin and 1 mg of alogliptin was transferred into 
a clean and dry Petridis. The Petridis was placed in direct sunlight 
for 5 d. In this study, the drug substance was exposed to direct 
sunlight for 5 d to determine the effect of irradiation on the stability 
of the drugs in solid-state. Afterward, the drug was transferred into 
a 10 ml volumetric flask and make up the volume with the mobile 
phase.1 ml of the above solution was transferred into a 10 ml 
volumetric flask and diluted with 10 ml using the mobile phase. The 
resultant solution was applied to the TLC plate in triplicate [17]. 
Preparation of dry heat degradation products 
Accurately weighed and transferred 40 mg of metformin and 1 mg of 
alogliptin was transferred into a clean and dry Petridis. The Petridis 
was placed in an oven at 50 °C for 3h. The drug was transferred into 
a 10 ml volumetric flask and make up the volume with mobile 
phase.1 ml of the above solution was transferred into a 10 ml 
volumetric flask and diluted with 10 ml using the mobile phase. The 
resultant solution was applied to the TLC plate in triplicate [17]. 
RESULTS AND DISCUSSION 
A novel, simple and precise HPTLC method coupled with 
densitometer was developed for the estimation of alogliptin and 
metformin present in the marketed formulation. Several analytical 
methods have been reported for the determination of metformin 
with alogliptin and combined with other drugs in pure and 
pharmaceutical dosage forms using spectrophotometry [3-5, 14], 
HPLC [6-8, 12, 15-17] Colorimetry [13]. Few methods like LC-
MS/MS for determination of alogliptin and voglibose inhuman 
plasma [19] are found in the literature but these methods are not 
preferred for routine analysis of alogliptin and metformin in bulk 
and formulation studies because of the high cost of analytical 
technique and the skilled requirement for sample treatment. There 
are some HPTLC methods [9-11, 18] reported in the literature but 
they have certain restrictions like requiring a large quantity of 
samples and organic solvents or sensitive to microgram 
concentration. In this work, new stability-indicating HPTLC method 
has been developed for the simultaneous estimation of the alogliptin 
and metformin. Initially, chloroform: methanol in ratio 4:6[v/v] was 
tried for both drugs simultaneously; the spots were not developed 
properly and dragging was observed. Then, chloroform: methanol in 
the ratio 6: 4 [v/v] was tried. The developed spots were diffused to 
the above mobile phase; 2 ml of 0.5 % ammonium sulphate was 
added. Both the peaks were symmetrical and no tailing was 
observed. Finally, the mobile phase consisting of chloroform: 
methanol: 0.5 % ammonium sulphate [4:4:2, v/v] gave good 
resolution. By optimizing chromatographic conditions such as 
having chamber saturation for 20 min, using 10 ml of the mobile 
phase and activating the plates before spotting and obtain a good 
resolution as well as a sharp and symmetrical peak with Rf value of 
0.44 ±0.02 for metformin and 0.66 ±0.02 for alogliptin. The method 
ensures minimal use of the mobile phase with minimal run time 
compared to other reported analytical methods. The ideal stability-
indicating chromatographic method should estimate the drug and 
also be able to resolve the drug from its degradation products. 
Accuracy results displayed good reproducibility with % RSD values 
2. This was found to be accurate as the percent recovery observed 
was high i.e. within the range of 98.84-100.4. The LOD of the 
developed HPTLC method was found to be 40 ng/spot for metformin 
and 1 ng/spot for alogliptin, respectively. The LOQ of the developed 
HPTLC method was found to be 130 ng/spot for metformin and 60 
ng/spot for alogliptin, respectively. It confirms the method is sensitive. 
Besides, the estimation of the marketed preparation of alogliptin and 
metfomin with the validated methods showed that the drug contents 
separated with no interfering peaks were generated by the excipients 
in the marketed formulation as shown in the fig. 5. The method is 
versatile and simple for the analysis of alogliptin and metformin in 
pure and pharmaceutical formulations. The method confirms minimal 
use of the mobile phase with a short run time compared to other 
reported analytical methods. The method was found to obey all the 
validation parameters as per ICH guidelines [20]. 
Validation of the developed method 
Linearity 
Metformin and alogliptin showed linearity in the range of 40-200 
ng/spot and 1-5 ng/spot respectively. The slope, intercept and 
correlation coefficient values for metformin were found to be 
4.3725, 501.5 and 0.997 respectively. The slope, intercept and 
correlation coefficient values for alogliptin were found to be 31.7, 
205.02 and 0.999 respectively. 
Precision 
Intra-day and Inter-day was found out by carrying out the analysis 
of the standard drug at three different concentrations of 80,120 and 
160 ng/spot for metformin 2,3 and 4 ng/spot for alogliptin were 
selected from linearity range. Repeatability was determined by 
applying the corresponding µl of a standard solution containing 120 
ng/spot of metformin and 3 ng/spot of alogliptin in six replicates. 
The % RSD was found to be less than 2%. 
Accuracy 
Accuracy of the method was determined by replicates [n=3] 
analysis, carried out using three solutions prepared by standard 
addition of pure active pharmaceutical ingredient at three different 
concentration levels 80 %, 100 % and 120%. Accuracy was 
calculated by comparing the difference between the spiked value 
[theoretical value] and the found value. Results are presented in the 
term of % recovery of the active pharmaceutical ingredient and data 
for both metformin and alogliptin. The summary of validation 
parameters was listed in table 1. 
Analysis of marketed formulation 
The chromatograms of the drugs are extracted from commercial 
formulation, exhibited two peaks at Rf value of 0.44 and 0.66 for 
metformin and alogliptin, respectively. The results of the analysis of 
the marketed formulation are given in table 2. 
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Table 1: Summary of validation parameters 
Parameters Metformin Alogliptin 
Linearity range [ng/spot] 40-200 1-5 
Correlation coefficient [R2] 0.996 0.997 
Slope 4.3725 31.7  
Intercept 501.58 205.02 
Limit of detection[ng/spot] 40 1 
Limit of quantification [ng/spot] 130 6 
% Recovery [n=3] 100.4 98.87 
Precision[%RSD], [ mean ± S. D]   
Repeatability of application [n=6] 1.18,1197±14.2 2.210,801.3 ± 17.6 
Intra-day [n=3] 0.58,1008.7±5.9 2.02,875.8±17.7 
Inter-day [n=3] 1.45,1221.9± 1.64,779.6±12.8 
% RSD =Relative standard deviation, SD=Standard deviation, n= number of injections 
 
Table 2: Analysis of marketed formulation 
Component Amount [ mg] % Label claim % RSD* 
Labeled Found 
Metformin 500 498 99.6 0.32  
 Alogliptin 12.5 12 96.0 0.85 
*Relative standard deviation; [n=5] 
 
Forced degradation results 
Peaks obtained from samples degraded by treatment with acid, base, 
hydrogen peroxide, dry heat treatment and photolytic contained well-
separated spots of the pure drugs and same additional peaks at 
different Rf
 
 values. It is apparent from [fig. 4-8] the spots of 
degradation products were well resolved from those of the drugs. The 
peaks of the metformin and alogliptin were not significantly shifted in 
the presence of the degradation peaks, which indicated the stability-
indicating the nature of the method. The results are shown in table 3. 
 
Fig. 4: Densitogram of acid-treated metformin and alogliptin 
 
 
Fig. 5: Densitogram of base treated metformin and alogliptin 
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Fig. 6: Densitogram of hydrogen peroxide-treated metformin and alogliptin 
 
 
Fig. 7: Densitogram of dry heat-treated metformin and alogliptin 
 
 
Fig. 8: Densitogram of light heat-treated metformin and alogliptin 
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CONCLUSION 
The present study represents an accurate, simple, specific, precise 
and stability-indicating HPTLC method has been developed for the 
quantitative determination of metformin and alogliptin in bulk drug 
and tablet formulation. The developed method was validated based 
on ICH guidelines. Non-requirement of skilled personnel to operate 
the instruments involved is an added advantage of this method. 
Therefore, the method can be applied for routine quality control 
analysis of metformin and alogliptin in active pharmaceutical 
ingredients and the combined dosage form. 
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